Jazz Pharmaceuticals settled patent litigation with Avadel Pharmaceuticals for $90 million, establishing royalty agreements and licenses for Lumryz and Xywav/Xyrem.
Kraft Heinz appointed L. Kevin Cox, Mary Lou Kelley, and Tony Palmer to its Board of Directors, leveraging their expertise for its ongoing transformation and planned separation.
ImageneBio appointed CEO Kristin Yarema as interim principal financial officer, effective October 21, 2025, according to a recent SEC filing.
Bakkt Holdings amends its management options proposal, significantly reducing the aggregate number of options from 7,450,000 to 2,000,000.
Greenidge Generation announced early results for its 8.50% Senior Notes due 2026 tender and exchange offer, with $276,225 tendered under the cash option.
Nurix Therapeutics launches its pivotal DAYBreak Phase 2 clinical trial for bexobrutideg in r/r CLL/SLL, seeking Accelerated Approval, and updates on NX-1607 trial data.